PORTLAND, OR--(Marketwire - May 13, 2008) - AVI BioPharma, Inc. (NASDAQ: AVII) today announced that treatment of non-human primates with either the antisense drug AVI-6002 or with the antisense drug AVI-6003, resulted in a reproducible and high rate of survival in the face of an otherwise lethal infection with Ebola or Marburg virus, respectively.
